Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV gp120 vaccine - VaxGen

Drug Profile

HIV gp120 vaccine - VaxGen

Alternative Names: AIDSVAX; AIDSVAX B/B'; AIDSVAX B/E; HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; VaxGen
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; Global Solutions for Infectious Diseases; International AIDS Vaccine Initiative; MRC/UVRI Uganda Research Unit on AIDS; VaxGen
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 07 Aug 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections in October 2018 (NCT03618056)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
  • 15 Mar 2017 EuroVacc Foundation initiates enrolment in the EV07 phase I trial for HIV-I infections (Prevention) in Uganda (NCT03391375)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top